To externally validate 'prostascore' in patients with metastatic hormone-sensitive prostate cancer recruited to the phase III CHAARTED study.
Introduction
As the fourth most common cancer in the world, prostate cancer constitutes a major health problem globally. According to GLOBOCAN data,~1.1 million patients were diagnosed with prostate cancer in 2012 [1] . Likewise, prostate cancer is an important cause of cancer mortality, being the fifth leading cause of cancer death in men [2] .
Approaches to the management of metastatic hormonesensitive prostate cancer vary based on a number of disease and patient factors. These include age, performance status and vital organ functions of the patient, as well as extent and biology of the disease [3] .Traditionally, metastatic prostate cancer was considered as one stage (stage IV) and one disease entity by different staging systems, including the American Joint Committee on Cancer staging system [4] ; there was therefore a lack of proper prognostic models in this particular setting when compared with either the localized disease or castrate-resistant disease setting [5] [6] [7] [8] .
More recently, a 'prostascore' model has been proposed to stratify patients with advanced untreated prostate cancer. This model relies on baseline PSA level, baseline grade and anatomical extent of the disease. Details of the scoring system have been published elsewhere [9] . The initial development and internal validation of this model were based on data from the Surveillance, Epidemiology and End Results (SEER) Recently, the National Cancer Institute (NCI) in collaboration with the Project Data Sphere launched an initiative to facilitate access to the raw data of landmark studies sponsored by the NCI [10] . As a result of this initiative, data from the CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) study were made available to researchers. Given the fact that the prostascore model can be applied to the patient population of the CHAARTED study, we aimed to determine how prostascore would perform in this patient population.
The objective of the present study was to externally validate the prostascore model in hormone-sensitive patients with prostate cancer recruited to the CHAARTED study. In addition, we aimed to evaluate the potential impact of the prostascore model on the choice of first-line treatment for metastatic hormone-sensitive prostate cancer.
Patients and Methods

Selection of the Study Cohort
The present study was based on the dataset from the CHAARTED study (E3805), conducted from July 2006 to December 2012, in which a total of 790 patients with hormone-sensitive metastatic prostate cancer were randomized to either androgen deprivation treatment (ADT) plus docetaxel or ADT alone. The date of database lock for overall and cause-specific survival analyses was 23 December 2013 and for progression-free survival and time to castrateresistant state it was 23 December 2014. The primary results of that study were published in 2015 [11] . The primary dataset of the study population was downloaded after relevant approvals were obtained from the NCI through the Project Data Sphere initiative. Patients with absent baseline information on Gleason score, PSA level or disease extent were excluded from further analyses.
Data Collection
The available study dataset contains information on age at enrolment into the study, race, baseline PSA and Gleason score, performance status, disease extent (low or high risk, visceral or non-visceral), previous local treatment to the primary (surgery or radiation therapy), previous adjuvant hormonal treatment, study treatment arm allocation, survival status, cause of death and survival months. According to the available protocol of the study, all included patients should have a performance status score ≤2 and adequate liver, renal and haematological variables. According to the study protocol, high risk was defined as the presence of visceral metastases or four or more bone lesions with at least one beyond the vertebral bodies and pelvis.
Prostascore was then calculated based on available information about baseline PSA, Gleason score (after being translated to appropriate grade group) [12] , and disease extent. For the purpose of calculation of prostascore, all patients with low-risk non-visceral metastases were considered to have bone metastases.
In the E3805 study, overall survival was defined as the time from randomization to death (from any cause) or date last known alive, progression-free survival was defined as the time from randomization to death, PSA progression, clinical progression or date of last known progression-free status, and time to castrate-resistant prostate cancer was defined as the time from randomization to PSA progression or clinical progression. Patients without disease progression were censored at the date of last disease assessment.
Statistical Analysis
Kaplan-Meier analysis and log-rank testing were used for survival comparisons for the whole cohort. In addition, a comparison of the two treatment arms among patients with different scores was conducted. The c-statistic was used to evaluate the ability of the model to predict overall and cancer-specific mortality in the study cohort. Cause-specific hazard ratios according to prostascore (adjusted for treatment arm disposition) were also reported for cancer-specific survival and time to castrate-resistant prostate cancer. A twotailed P value <0.05 was taken to indicate statistical significance. Statistical procedures were carried out using SPSS Statistics 20.0 (IBM, Armonk, NY, USA).
Ethics
As this study was based on a publicly available dataset with no identifying patient information, informed consent was not needed.
Results
Of the total 790 patients in the study, 88 were found to have absent Gleason scores and/or baseline PSA levels and were therefore excluded. This left a total of 702 patients with complete baseline data, allowing the calculation of prostascore ( Table 1) . The median (range) follow up was 23.4 (0.5-79.7) months. In all, 77.7% of the study population were aged <70 years and 85.8% were white. Approximately 99% of patients had a performance score of 0-1. Metastatic disease was considered low risk in 36.9% of patients and high risk in 63.1%. Visceral disease was diagnosed in 14.8% of patients. Approximately 21.2% of the patients had undergone previous surgery and 8% had undergone previous radiotherapy. Adjuvant hormonal treatment was undergone by 4.7% of patients. Among the 702 patients in the present analysis, 355 (50.6%) received combined chemo-hormonal treatment, while 347 (49.4%) received ADT only. ADT was planned as combined androgen blockade in 43.3%. After disease progression, 58.7% of patients did not receive any lifeprolonging treatments, 21.5% received one life-prolonging treatment and 19.8% received two or more life-prolonging treatments. Subsequent treatments beyond progression included: docetaxel, cabazitaxel, mitoxantrone, abiraterone, enzalutamide, antiandrogens, Spuliceul-T and palliative radiotherapy.
Survival Outcomes
Overall survival was assessed according to prostascore in the whole cohort. The P value for overall survival trend was significant (P < 0.001; Fig. 1A ). Likewise, progression-free survival was assessed according to prostascore in the whole cohort and the P value for progression-free survival trend was also significant (P < 0.001; Fig. 1B ).
Overall survival comparisons according to treatment arm were further evaluated among different prostascores. Notably, the P value for overall survival difference was not significant for prostascore 2 (P = 0.702), but was significant for prostascores 3, 4 and 5 (P < 0.05; Fig. 1A-D) .
The cause-specific hazard ratio for cancer-specific survival (adjusted for treatment arm used) was evaluated and the P value for pairwise comparisons was significant for different scores (P < 0.01) except for the comparison between scores 4 and 5 ( Fig. 2A) . Likewise, the cause-specific hazard ratio for time to castrate-resistant state (adjusted for treatment arm used) was evaluated and the P value for pairwise comparisons was significant for different scores (P < 0.01) except for the comparison between scores 4 and 5 (Fig. 2B) .
The c-statistic was calculated to validate the predictive ability of prostascore for both overall and cancer-specific survival. Using death from any cause as the dependent variable, the c-statistic was: 0.609 (SE 0.022; 95% CI: 0.565-0.653). Likewise, using death from prostate cancer as the dependent variable, the c-statistic was: 0.621 (SE 0.023; 95% CI: 0.576-0666).
Discussion
The present study validates the recently proposed prostascore model for advanced prostate cancer in an external dataset. The results showed that prostascore can successfully stratify patients with metastatic prostate cancer into different categories with variable overall and progression-free survival outcomes. Patients with higher scores seem to benefit more Compared with the original prostascore publication, which was based on the SEER database, the present study has some weaknesses and strengths. The primary weakness compared with the original publication is the relatively small overall number of patients (702 patients in the present study vs 8 272 patients in the original publication). Strengths of the present study include the following: (i) the prospective controlled nature of the present dataset provides much more reliable data compared with the retrospective, registry-based nature of the SEER dataset; (ii) systemic treatment data (even beyond progression after first-line therapy) are detailed in the present study, but were not available in the SEER database; (iii) functional information about patients (including performance status and vital organ functions) are detailed for the present study but are absent from the SEER database; (iv) the SEER database provides information only about the impact of prostascore on overall and cancer-specific survival, while the present study provides insight into the impact of prostascore on progression-free survival and time to castrateresistant state development; and (v) the E3805 study recruitment and follow-up period (2006-2014) was much longer than the short follow-up period on which the previous SEER-based analysis was based (2010-2013).
The c-statistic for prostate cancer-specific survival in the present dataset was 0.621 which is lower than c-statistic for the prostate cancer-specific survival in the internal validation cohort of the original prostascore publication (0.728). This could be explained by the smaller sample size in the present analysis.
External validation of prognostic indices is fundamental before embarking on long-term commitment to their use in clinical practice. This is because external validation supports the reliability of the prognostic index in clinical practice. The present study therefore represents an important step in the development process of prostascore. It should be noted, however, that the structure of the available E3805 dataset is slightly different from the SEER dataset on which the model was first proposed. While the SEER dataset included patients with advanced prostate cancer (including patients with regional lymphadenopathy), the E3805 study included only patients with M1 disease; thus, prostascores of 0 and 1 were not represented in the E3805 dataset.
P values for pairwise hazard ratio comparisons for both cancer-specific survival and time to castrate-resistant disease were significant for all comparisons except for that between scores 4 and 5. This is probably because of the small number of patients in the score 5 category (45 patients) which hindered the detection of statistically significant differences.
According to the results of the E3805 study, patients with high-risk metastatic disease seem to derive the highest benefit from combined chemo-hormonal treatment. Many guidelines therefore suggest restricting the use of combined chemohormonal treatment to patients with high-risk metastatic disease [13] . The results of the present study suggest that prostascore might provide a more refined way of selecting patients for more or less aggressive treatment (the higher the score, the more likely the patient would benefit from combination treatment). This might prove helpful in the patient counselling process as well as in supporting the decision-making process in multidisciplinary discussions.
More recently, data presented at American Society of Clinical Oncology 2017 and published concurrently in the New England Journal of Medicine suggest that abiraterone/ADT combination is better than ADT alone in the first-line treatment of metastatic hormone-sensitive prostate cancer [14, 15] . Whether prostascore could help stratify the benefit derived from this regimen will need further evaluation.
In conclusion, the present study confirms the potential role of prostascore in predicting the outcomes of patients with hormone-sensitive metastatic prostate cancer. Moreover, it highlights its potential role in therapeutic decision-making and patient counselling.
